Stocksigma LogoStocksigma Logo

Orchid Pharma Reports QIP Proceeds Utilization and Project Timeline Revisions

Orchid Pharma Limited reported full utilization of its ₹400 crore QIP proceeds for the quarter ended 30th Sep'26 following shareholder-approved

Orchid Pharma Reports QIP Proceeds Utilization and Project Timeline Revisions

Orchid Pharma Ltd · Others (Uncategorized) · 14 Nov 2026, 10:03 pm

Orchid Pharma Reports QIP Proceeds Utilization and Project Timeline Revisions Orchid Pharma Limited reported full utilization of its ₹400 crore QIP proceeds for the quarter ended 30th Sep'26 following shareholder-approved reallocation. Funds were reallocated from the postponed Alathur API expansion (cut to ₹0.36 crore) toward Orchid Bio-Pharma's Jammu facility (raised to ₹135 crore), debt prepayment (raised to ₹195.46 crore), and general corporate purposes (₹63.72 crore). Commercial operations at the greenfield Jammu manufacturing facility face significant delays due to ongoing land acquisition and farmer agreement procedures, with commercial startup now rescheduled to Feb'27.

Original exchange filing (PDF)

More announcements from Orchid Pharma Ltd

All Orchid Pharma Ltd announcements